RO111991B1 - Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare - Google Patents

Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare Download PDF

Info

Publication number
RO111991B1
RO111991B1 RO94-00409A RO9400409A RO111991B1 RO 111991 B1 RO111991 B1 RO 111991B1 RO 9400409 A RO9400409 A RO 9400409A RO 111991 B1 RO111991 B1 RO 111991B1
Authority
RO
Romania
Prior art keywords
interferon
thymosin
treatment
patients
hepatitis
Prior art date
Application number
RO94-00409A
Other languages
English (en)
Romanian (ro)
Inventor
Paul Chretian
Milton Mutchnick
Kenneth E Sherman
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick filed Critical Alpha 1 Biomedicals Inc
Publication of RO111991B1 publication Critical patent/RO111991B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
RO94-00409A 1991-09-13 1992-09-08 Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare RO111991B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (1)

Publication Number Publication Date
RO111991B1 true RO111991B1 (ro) 1997-04-30

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
RO94-00409A RO111991B1 (ro) 1991-09-13 1992-09-08 Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare

Country Status (23)

Country Link
US (3) US6001799A (enExample)
EP (1) EP0603305B1 (enExample)
JP (1) JP3228512B2 (enExample)
KR (1) KR100254082B1 (enExample)
AT (1) ATE152914T1 (enExample)
AU (1) AU667327B2 (enExample)
CA (1) CA2119006C (enExample)
CZ (1) CZ286827B6 (enExample)
DE (1) DE69219782T2 (enExample)
DK (1) DK0603305T3 (enExample)
ES (1) ES2103966T3 (enExample)
FI (1) FI107879B (enExample)
GR (1) GR3024025T3 (enExample)
HK (1) HK1021687A1 (enExample)
HU (1) HU221006B1 (enExample)
MX (1) MX9205240A (enExample)
NO (1) NO941310D0 (enExample)
RO (1) RO111991B1 (enExample)
RU (1) RU2104010C1 (enExample)
SG (1) SG64897A1 (enExample)
TW (1) TW224053B (enExample)
WO (1) WO1993005806A1 (enExample)
ZA (1) ZA926964B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
KR100298859B1 (ko) * 1993-11-05 2001-10-22 더 보드 오브 가버너스 오브 웨인 스테이트 유니버시티 대상부전성간질환을가진환자의치료방법및조성물
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
AU722987B2 (en) * 1996-02-28 2000-08-17 Unihart Corporation Pharmaceutical compositions comprising natural human alpha-interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
IL154299A0 (en) * 2000-08-07 2003-09-17 Sciclone Pharmaceuticals Inc Treatment of hepatitis c with thymosin, interferon and ribavirin
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
HUP0600449A2 (en) * 2001-10-05 2006-09-28 Intermune Methods of treating liver fibrosis and hepatitis c virus infection
CN1269524C (zh) 2001-10-26 2006-08-16 罗得岛医院 胸腺素强化的遗传免疫方法
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
CA2520400C (en) 2003-03-28 2013-02-19 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
PL1658302T3 (pl) 2003-07-25 2011-03-31 Idenix Pharmaceuticals Inc Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CA2580457C (en) 2004-09-14 2014-11-04 Pharmasset, Inc. Preparation of 2'­fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
ES2422290T3 (es) 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
ES2389452T3 (es) * 2006-05-02 2012-10-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de timosina 1, sola o en combinación con PTX3 o ganciclovir, para el tratamiento de infección por citomegalovirus
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
NO941310L (no) 1994-04-12
KR100254082B1 (ko) 2000-09-01
TW224053B (enExample) 1994-05-21
FI941133L (fi) 1994-03-10
HU221006B1 (hu) 2002-07-29
US20070218033A1 (en) 2007-09-20
MX9205240A (es) 1993-07-01
HU9400758D0 (en) 1994-06-28
DK0603305T3 (da) 1997-09-01
US5849696A (en) 1998-12-15
RU2104010C1 (ru) 1998-02-10
FI941133A0 (fi) 1994-03-10
RU94022480A (ru) 1996-07-20
CA2119006A1 (en) 1993-04-01
EP0603305A1 (en) 1994-06-29
DE69219782D1 (de) 1997-06-19
AU2644792A (en) 1993-04-27
EP0603305B1 (en) 1997-05-14
JPH06510998A (ja) 1994-12-08
AU667327B2 (en) 1996-03-21
JP3228512B2 (ja) 2001-11-12
ZA926964B (en) 1993-04-26
DE69219782T2 (de) 1997-10-09
SG64897A1 (en) 1999-05-25
CZ55194A3 (en) 1994-10-19
NO941310D0 (no) 1994-04-12
WO1993005806A1 (en) 1993-04-01
ATE152914T1 (de) 1997-05-15
ES2103966T3 (es) 1997-10-01
HUT75166A (en) 1997-04-28
FI107879B (fi) 2001-10-31
US6001799A (en) 1999-12-14
HK1021687A1 (en) 2000-06-23
GR3024025T3 (en) 1997-10-31
CZ286827B6 (cs) 2000-07-12
CA2119006C (en) 2005-08-23

Similar Documents

Publication Publication Date Title
RO111991B1 (ro) Metoda de tratament al hepatitei c si compozitie farmaceutica pentru tratare
HK1021687B (en) Use of a thymosin in the treatment of hepatitis c
SK149199A3 (en) Polyethylene glycol-interferon alpha conjugates for therapy of infection
Douglas et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM
Podzamczer et al. Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma
WO1994001125A1 (en) Composition and method of treating hepatitis b
WO1994001125A9 (en) Composition and method of treating hepatitis b
KR100306024B1 (ko) 인터페론치료에대한무반응자의c형간염치료조성물
Farhat et al. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B
KR20140035305A (ko) C형 간염 바이러스 감염의 새로운 치료법
KR100394382B1 (ko) 천연사람α-인터페론으로구성된약학조성물
Mauser‐Bunschoten et al. Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C
Northfelt et al. Continuous, low‐dose therapy with interferon‐α for human immunodeficiency virus (HIV)‐related immune thrombocytopenic purpura
Yabrov It is hazardous to treat HIV patients with interferon-α
AU751199B2 (en) Composition and method of treating hepatitis B
JPH07258109A (ja) Ｃ型肝炎の処置法および処置用組成物
Naoum et al. Treatment of herpes zoster with interferon alpha-2A.
Pockros Current status of immunomodulatory therapies in HCV infection
Ben-Noun Interferon Therapy in Liver Cirrhosis Type C
Lopez et al. Successful Antioxidant Therapy Including Superoxide Dismutase Associated with Antiretroviral Therapy in an HIV-Infected Patient with Hepatitis B-related Cirrhosis